Funds › Sector Gamma AS
Sector Gamma AS
13F for Q3 2026, filed Nov 12, 2026. 41 positions worth $485.0M.Managers with more than $100 million in US-listed stocks list their holdings each quarter, within 45 days of quarter end. Long positions only: no short sales or cash.
Ask your AI about this
Connect Claude, ChatGPT, Gemini or Grok (Microsoft 365 Copilot coming soon) to 13F.ai and ask in plain English. Copy a question to get started:
Using 13F.ai, what are the biggest new, added, trimmed and exited positions of Sector Gamma AS in the latest 13F quarter?
Using 13F.ai, how has Sector Gamma AS's portfolio concentration changed over the last four quarters?
Using 13F.ai, which of Sector Gamma AS's top holdings have also been bought by insiders recently?
Connect your AI · Plans and the 7-day free trial (card required)
Holdings, Q3 2026
Largest first. Common shares only.
| # | The fund's own figures at the end of the quarter. A report can be up to 45 days old when it is filed. Options and bonds are not counted here. | Filing | ||||
|---|---|---|---|---|---|---|
| 1 | BMY Bristol-Myers Squibb Company | 612,962 | $38.2M | 7.9% | -15.6% | 13F ↗ |
| 2 | PFE Pfizer, Inc. | 1.27M | $36.1M | 7.5% | +26.2% | 13F ↗ |
| 3 | MDT Medtronic plc. | 381,245 | $32.9M | 6.8% | +8.2% | 13F ↗ |
| 4 | MRK Merck & Company, Inc. | 193,044 | $28.1M | 5.8% | -11.0% | 13F ↗ |
| 5 | INCY Incyte Corporation | 155,100 | $18.8M | 3.9% | -9.2% | 13F ↗ |
| 6 | BMRN BioMarin Pharmaceutical Inc. | 293,293 | $17.6M | 3.6% | -0.6% | 13F ↗ |
| 7 | CVS CVS Health Corporation | 196,574 | $16.8M | 3.5% | +26.5% | 13F ↗ |
| 8 | GEHC GE HealthCare Technologies Inc. | 256,906 | $16.8M | 3.5% | +23.6% | 13F ↗ |
| 9 | ELV Elevance Health, Inc. | 40,229 | $15.6M | 3.2% | -9.6% | 13F ↗ |
| 10 | BIIB Biogen Inc. | 66,646 | $15.1M | 3.1% | +23.0% | 13F ↗ |
| 11 | IONS Ionis Pharmaceuticals, Inc. | 330,037 | $14.7M | 3.0% | +74.2% | 13F ↗ |
| 12 | BRKR Bruker Corporation | 217,352 | $14.1M | 2.9% | +42.7% | 13F ↗ |
| 13 | DHR Danaher Corporation | 63,381 | $14.0M | 2.9% | New | 13F ↗ |
| 14 | ABT Abbott Laboratories | 141,741 | $14.0M | 2.9% | -3.9% | 13F ↗ |
| 15 | BDX Becton, Dickinson and Company | 75,630 | $13.5M | 2.8% | -18.8% | 13F ↗ |
| 16 | BSX Boston Scientific Corporation | 308,128 | $13.4M | 2.8% | +154% | 13F ↗ |
| 17 | BIO Bio-Rad Laboratories, Inc. Class A | 33,350 | $12.6M | 2.6% | Unchanged | 13F ↗ |
| 18 | ZBH Zimmer Biomet Holdings, Inc. | 131,484 | $11.7M | 2.4% | -7.6% | 13F ↗ |
| 19 | IQV IQVIA Holdings, Inc. | 42,283 | $11.4M | 2.3% | -45.8% | 13F ↗ |
| 20 | REGN Regeneron Pharmaceuticals, Inc. | 14,184 | $10.8M | 2.2% | -10.1% | 13F ↗ |
| 21 | QGEN Qiagen N.V. | 231,170 | $10.1M | 2.1% | -19.6% | 13F ↗ |
| 22 | LH Labcorp Holdings Inc. | 31,019 | $9.6M | 2.0% | +19.2% | 13F ↗ |
| 23 | AVTR Avantor, Inc. | 606,088 | $9.1M | 1.9% | -33.1% | 13F ↗ |
| 24 | CAH Cardinal Health, Inc. | 40,301 | $9.0M | 1.8% | -1.0% | 13F ↗ |
| 25 | CNC Centene Corporation | 142,405 | $8.8M | 1.8% | -12.3% | 13F ↗ |
| 26 | UNH UnitedHealth Group Incorporated | 20,000 | $7.3M | 1.5% | New | 13F ↗ |
| 27 | AZN AstraZeneca PLC | 45,049 | $7.3M | 1.5% | New | 13F ↗ |
| 28 | PTCT PTC Therapeutics, Inc. | 112,000 | $7.3M | 1.5% | +12.0% | 13F ↗ |
| 29 | IOVA Iovance Biotherapeutics, Inc. | 388,466 | $5.8M | 1.2% | -59.9% | 13F ↗ |
| 30 | EW Edwards Lifesciences Corporation | 60,402 | $5.2M | 1.1% | Unchanged | 13F ↗ |
| 31 | KURA Kura Oncology, Inc. | 433,012 | $4.6M | 1.0% | Unchanged | 13F ↗ |
| 32 | SNDX Syndax Pharmaceuticals, Inc. | 241,739 | $4.5M | 0.9% | Unchanged | 13F ↗ |
| 33 | TNDM Tandem Diabetes Care, Inc. | 267,091 | $4.4M | 0.9% | Unchanged | 13F ↗ |
| 34 | HCA HCA Healthcare, Inc. | 10,000 | $4.3M | 0.9% | New | 13F ↗ |
| 35 | ASND Ascendis Pharma A/S | 18,305 | $4.2M | 0.9% | -14.1% | 13F ↗ |
| 36 | TVTX Travere Therapeutics, Inc. | 68,000 | $4.0M | 0.8% | -15.0% | 13F ↗ |
| 37 | MDGL Madrigal Pharmaceuticals, Inc. | 6,500 | $3.3M | 0.7% | New | 13F ↗ |
| 38 | CYTK Cytokinetics, Incorporated | 45,000 | $3.0M | 0.6% | Unchanged | 13F ↗ |
| 39 | DNLI Denali Therapeutics Inc. | 137,718 | $2.8M | 0.6% | New | 13F ↗ |
| 40 | ARDX Ardelyx, Inc. | 686,844 | $2.3M | 0.5% | Unchanged | 13F ↗ |
| 41 | VRDN Viridian Therapeutics, Inc. | 84,867 | $1.7M | 0.4% | New | 13F ↗ |
Changes since Q2 2026
7 new, 10 added to, 17 trimmed, 6 exited, 7 unchanged. By estimated dollars.
New positions (7)
| DHR Danaher Corporation | 63,381 | New | $14.0M |
| UNH UnitedHealth Group Incorporated | 20,000 | New | $7.3M |
| AZN AstraZeneca PLC | 45,049 | New | $7.3M |
| HCA HCA Healthcare, Inc. | 10,000 | New | $4.3M |
| MDGL Madrigal Pharmaceuticals, Inc. | 6,500 | New | $3.3M |
| DNLI Denali Therapeutics Inc. | 137,718 | New | $2.8M |
| VRDN Viridian Therapeutics, Inc. | 84,867 | New | $1.7M |
Added to (10)
| BSX Boston Scientific Corporation | 308,128 | +154% | $8.2M |
| PFE Pfizer, Inc. | 1.27M | +26.2% | $7.5M |
| IONS Ionis Pharmaceuticals, Inc. | 330,037 | +74.2% | $6.3M |
| BRKR Bruker Corporation | 217,352 | +42.7% | $4.2M |
| CVS CVS Health Corporation | 196,574 | +26.5% | $3.5M |
| GEHC GE HealthCare Technologies Inc. | 256,906 | +23.6% | $3.2M |
| BIIB Biogen Inc. | 66,646 | +23.0% | $2.8M |
| MDT Medtronic plc. | 381,245 | +8.2% | $2.5M |
| LH Labcorp Holdings Inc. | 31,019 | +19.2% | $1.5M |
| PTCT PTC Therapeutics, Inc. | 112,000 | +12.0% | $777.4K |
Trimmed (17)
| IQV IQVIA Holdings, Inc. | 42,283 | -45.8% | -$9.6M |
| IOVA Iovance Biotherapeutics, Inc. | 388,466 | -59.9% | -$8.6M |
| BMY Bristol-Myers Squibb Company | 612,962 | -15.6% | -$7.1M |
| AVTR Avantor, Inc. | 606,088 | -33.1% | -$4.5M |
| MRK Merck & Company, Inc. | 193,044 | -11.0% | -$3.5M |
| BDX Becton, Dickinson and Company | 75,630 | -18.8% | -$3.1M |
| QGEN Qiagen N.V. | 231,170 | -19.6% | -$2.5M |
| INCY Incyte Corporation | 155,100 | -9.2% | -$1.9M |
| ELV Elevance Health, Inc. | 40,229 | -9.6% | -$1.7M |
| CNC Centene Corporation | 142,405 | -12.3% | -$1.2M |
The 10 largest of each, by estimated dollars: shares changed times the later report's price. Index tracking, splits and mergers move positions too.
Compare two quarters
Pick any two quarters: what is new, added to, trimmed or exited. Premium plan.
Reported value by quarter
Value and number of positions at the end of each quarter.
Loading…
Largest positions in earlier quarters
Pick a quarter to see what the fund's biggest positions were then.
Loading…
Ten largest positions
By value, Q3 2026.
Filings
| Filing | ||||||
|---|---|---|---|---|---|---|
| Q3 2026 | Nov 12, 2026 | 13F-HR | 41 | $485.0M | Current | SEC ↗ |
| Q2 2026 | Aug 12, 2026 | 13F-HR | 40 | $461.0M | Current | SEC ↗ |
| Q1 2026 | May 7, 2026 | 13F-HR | 42 | $423.5M | Current | SEC ↗ |
| Q4 2025 | Feb 12, 2026 | 13F-HR | 36 | $438.7M | Current | SEC ↗ |
| Q3 2025 | Oct 31, 2025 | 13F-HR | 41 | $403.3M | Current | SEC ↗ |
| Q2 2025 | Jul 31, 2025 | 13F-HR | 38 | $305.9M | Current | SEC ↗ |
| Q1 2025 | May 13, 2025 | 13F-HR | 33 | $312.2M | Current | SEC ↗ |
Most recent first, up to 80. An amendment can replace a report or add holdings to it. All 13F filings
Information, not investment advice. Values are the fund's own figures at quarter end; a report can be up to 45 days old when filed. Disclaimer